Assembly Biosciences Inc
Company Profile
Business description
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Contact
Two Tower Place
7th Floor
South San FranciscoCA94080
USAT: +1 833 509-4583
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
73
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,341.00 | 53.10 | 0.64% |
| CAC 40 | 7,584.88 | 29.01 | 0.38% |
| DAX 40 | 22,539.42 | 113.59 | 0.51% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,467.31 | 3.85 | 0.05% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 36,045.38 | 205.39 | 0.57% |
| NZX 50 Index | 11,903.31 | 122.14 | -1.02% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,126.20 | 55.60 | 0.69% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |